Brief: Compugen Publishes Review On Biology And Potential Therapeutic Relevance Of Dnam-1 Axis In Cancer Immunotherapy
09/03/2021 12:41
March 9 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN PUBLISHES REVIEW ON BIOLOGY AND POTENTIAL
THERAPEUTIC
RELEVANCE OF DNAM-1 AXIS IN CANCER IMMUNOTHERAPY
Source text for Eikon: ID:nPn7TrPPda
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025